This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory tract | 3324 |
virus infection | 2995 |
respiratory syncytial | 2140 |
acute respiratory | 2090 |
syncytial virus | 2051 |
viral infections | 2048 |
influenza virus | 1949 |
immune response | 1735 |
infection control | 1678 |
united states | 1513 |
clinical signs | 1432 |
viral infection | 1426 |
infectious diseases | 1317 |
risk factors | 1273 |
respiratory infections | 1262 |
epithelial cells | 1259 |
respiratory syndrome | 1252 |
immune responses | 1251 |
transplant recipients | 1238 |
lower respiratory | 1229 |
tract infections | 1197 |
respiratory viruses | 1191 |
intensive care | 1174 |
health care | 1163 |
immune system | 1152 |
may also | 1043 |
upper respiratory | 1020 |
severe acute | 1016 |
staphylococcus aureus | 1004 |
hand hygiene | 989 |
public health | 932 |
bone marrow | 896 |
virus infections | 885 |
type i | 855 |
influenza viruses | 766 |
tract infection | 760 |
nk cells | 759 |
bacterial infections | 751 |
care unit | 747 |
infected cells | 740 |
nervous system | 733 |
viral replication | 721 |
systematic review | 716 |
innate immune | 707 |
immunodeficiency virus | 698 |
mg kg | 667 |
human metapneumovirus | 661 |
herpes simplex | 649 |
doc id | 647 |
cord uid | 647 |
gene expression | 640 |
may occur | 639 |
infectious disease | 635 |
respiratory infection | 629 |
young children | 615 |
increased risk | 604 |
respiratory viral | 601 |
stem cell | 594 |
influenza infection | 593 |
central nervous | 572 |
respiratory disease | 571 |
bacterial infection | 566 |
lymph nodes | 558 |
viral load | 555 |
guinea pigs | 551 |
virus replication | 550 |
rsv infection | 546 |
avian influenza | 546 |
chain reaction | 542 |
pregnant women | 535 |
polymerase chain | 532 |
urinary tract | 531 |
hiv infection | 530 |
clinical trials | 530 |
novel coronavirus | 528 |
dengue virus | 525 |
nosocomial infections | 514 |
severe disease | 513 |
respiratory distress | 506 |
animal models | 506 |
dendritic cells | 504 |
respiratory virus | 498 |
common cold | 495 |
simplex virus | 495 |
breast milk | 493 |
zika virus | 492 |
human immunodeficiency | 490 |
escherichia coli | 487 |
immunocompromised patients | 481 |
pandemic influenza | 475 |
infected patients | 475 |
risk factor | 473 |
inflammatory response | 473 |
weight loss | 471 |
infectious agents | 456 |
west nile | 453 |
antiviral activity | 451 |
peripheral blood | 450 |
rhinovirus infection | 450 |
host cell | 446 |
ebola virus | 444 |
infection may | 441 |
hemorrhagic fever | 440 |
clinical manifestations | 440 |
healthcare workers | 432 |
syndrome coronavirus | 429 |
virus type | 429 |
fungal infections | 428 |
respiratory illness | 427 |
viral rna | 427 |
otitis media | 424 |
resistant staphylococcus | 420 |
cell culture | 418 |
infection rates | 418 |
lung transplant | 417 |
hong kong | 412 |
incubation period | 406 |
viral respiratory | 406 |
gastrointestinal tract | 400 |
cell lines | 395 |
acquired pneumonia | 393 |
controlled trial | 392 |
years old | 389 |
differential diagnosis | 386 |
critically ill | 385 |
infection prevention | 385 |
amino acid | 382 |
nile virus | 381 |
cell responses | 381 |
case report | 380 |
clinical features | 380 |
nk cell | 379 |
nosocomial infection | 376 |
coronavirus disease | 373 |
antibiotic therapy | 370 |
cell transplantation | 370 |
pseudomonas aeruginosa | 369 |
host immune | 369 |
prospective study | 368 |
world health | 366 |
disease control | 365 |
high risk | 363 |
mg dl | 362 |
direct contact | 361 |
clinical disease | 361 |
infected mice | 360 |
parainfluenza virus | 359 |
infected individuals | 358 |
nucleic acid | 357 |
time pcr | 357 |
developing countries | 357 |
streptococcus pneumoniae | 357 |
human rhinovirus | 356 |
natural killer | 353 |
may result | 352 |
seasonal influenza | 352 |
control measures | 351 |
monoclonal antibodies | 350 |
disease severity | 349 |
cell death | 349 |
clinical symptoms | 348 |
important role | 347 |
mortality rate | 347 |
pulmonary disease | 340 |
infection rate | 338 |
immune cells | 338 |
mouse model | 338 |
one study | 337 |
middle east | 335 |
monoclonal antibody | 334 |
solid organ | 333 |
respiratory symptoms | 333 |
cystic fibrosis | 331 |
necrosis factor | 327 |
secondary bacterial | 326 |
adaptive immune | 326 |
hematopoietic stem | 324 |
inflammatory cytokines | 320 |
hospitalized patients | 320 |
health organization | 320 |
primary immunodeficiency | 318 |
host cells | 318 |
antimicrobial resistance | 317 |
may cause | 317 |
experimental infection | 314 |
lung disease | 314 |
nitric oxide | 313 |
fever virus | 312 |
neonatal intensive | 312 |
neutralizing antibodies | 311 |
infl uenza | 311 |
bacterial pneumonia | 311 |
mycobacterium tuberculosis | 310 |
organ transplant | 309 |
liver disease | 307 |
central venous | 304 |
innate immunity | 300 |
may lead | 298 |
common cause | 297 |
mechanical ventilation | 296 |
rna viruses | 295 |
clinical presentation | 294 |
distress syndrome | 293 |
human bocavirus | 292 |
clinical trial | 291 |
clostridium difficile | 289 |
severe cases | 286 |
antibiotic treatment | 284 |
mortality rates | 283 |
general population | 283 |
asthma exacerbations | 282 |
significantly higher | 282 |
high levels | 280 |
septic shock | 278 |
endothelial cells | 278 |
clinical characteristics | 277 |
primary infection | 276 |
tumor necrosis | 275 |
antibody response | 274 |
care units | 274 |
antimicrobial therapy | 274 |
associated infections | 272 |
recent study | 271 |
rv infection | 270 |
respiratory failure | 270 |
cohort study | 268 |
least one | 267 |
care workers | 266 |
encephalitis virus | 266 |
north america | 266 |
human respiratory | 265 |
side effects | 264 |
cell types | 264 |
vertical transmission | 264 |
infected animals | 264 |
electron microscopy | 261 |
ill patients | 261 |
cell surface | 260 |
antimicrobial agents | 260 |
renal failure | 259 |
nipah virus | 259 |
coronavirus infection | 257 |
host response | 256 |
antibody responses | 255 |
like receptor | 255 |
cell transplant | 255 |
respiratory pathogens | 254 |
recent studies | 254 |
influenza vaccine | 253 |
abdominal pain | 253 |
infections may | 253 |
clinical practice | 253 |
per year | 252 |
commonly used | 250 |
east respiratory | 250 |
blood cultures | 249 |
lung transplantation | 248 |
among children | 248 |
severe respiratory | 247 |
infections caused | 247 |
high mortality | 246 |
stranded rna | 246 |
care facilities | 244 |
immune deficiency | 243 |
small intestine | 243 |
highly pathogenic | 243 |
cd cd | 242 |
closely related | 241 |
age groups | 240 |
mononuclear cells | 239 |
yellow fever | 239 |
antibiotic resistance | 239 |
chlamydia pneumoniae | 237 |
sore throat | 237 |
chronic obstructive | 237 |
animal model | 237 |
opportunistic infections | 237 |
lung injury | 235 |
several studies | 233 |
cmv infection | 233 |
statistically significant | 233 |
bronchoalveolar lavage | 233 |
flow cytometry | 232 |
acute infection | 232 |
rotavirus infection | 232 |
barr virus | 232 |
bacterial pathogens | 231 |
total number | 231 |
associated pneumonia | 231 |
mice infected | 231 |
guinea pig | 230 |
bloodstream infections | 230 |
i ifn | 229 |
cytokine production | 229 |
human coronavirus | 229 |
valley fever | 229 |
vaccine development | 228 |
transplant patients | 227 |
rift valley | 225 |
sendai virus | 225 |
body fluids | 224 |
viral shedding | 224 |
tract disease | 224 |
pediatric patients | 223 |
class i | 222 |
cd cells | 222 |
negative bacteria | 222 |
alveolar macrophages | 222 |
combined immunodeficiency | 221 |
adult patients | 220 |
may develop | 220 |
obstructive pulmonary | 219 |
acute phase | 218 |
present study | 218 |
large number | 217 |
patients infected | 216 |
hepatitis virus | 216 |
infected cats | 216 |
sars coronavirus | 216 |
type ii | 214 |
life cycle | 214 |
clinical course | 213 |
causative agent | 213 |
higher risk | 212 |
live attenuated | 212 |
recent years | 212 |
physical examination | 212 |
randomized controlled | 211 |
among patients | 210 |
days post | 210 |
i interferon | 209 |
viral pathogens | 209 |
wide range | 209 |
adverse events | 207 |
protective equipment | 206 |
viral proteins | 206 |
age group | 206 |
disease progression | 206 |
diabetes mellitus | 205 |
rights reserved | 205 |
experimentally infected | 205 |
united kingdom | 205 |
zoster virus | 204 |
viral pneumonia | 204 |
host defense | 204 |
immune function | 204 |
hospitalized children | 204 |
lung function | 203 |
viral loads | 203 |
leukemia virus | 203 |
multiple sclerosis | 203 |
lymph node | 202 |
rhinovirus infections | 202 |
may contribute | 201 |
data suggest | 201 |
chronic infection | 200 |
interstitial pneumonia | 200 |
persistent infection | 200 |
influenza vaccination | 200 |
major cause | 200 |
cell line | 199 |
cytokine storm | 199 |
cell count | 199 |
body weight | 199 |
care settings | 198 |
chikungunya virus | 198 |
infections among | 197 |
infl ammatory | 197 |
neutralizing antibody | 197 |
vaccinia virus | 197 |
within days | 196 |
organ transplantation | 196 |
respiratory secretions | 196 |
feline immunodeficiency | 195 |
antibody titers | 195 |
increased susceptibility | 195 |
human infection | 195 |
human disease | 194 |
airway epithelial | 194 |
soft tissue | 193 |
resistant strains | 193 |
patients may | 193 |
introduction background | 193 |
performed using | 193 |
antiviral therapy | 193 |
heart failure | 192 |
birth weight | 191 |
measles virus | 190 |
haemophilus influenzae | 190 |
less common | 190 |
experimental rhinovirus | 190 |
mucous membranes | 189 |
antibiotic use | 189 |
like illness | 189 |
disease virus | 188 |
marrow transplantation | 188 |
clinical studies | 188 |
blood cells | 187 |
new york | 186 |
previously described | 186 |
clinical isolates | 186 |
even though | 186 |
severe covid | 186 |
infected children | 186 |
iav infection | 184 |
epithelial cell | 184 |
naturally occurring | 184 |
recurrent infections | 184 |
influenza pandemic | 183 |
lymphocytic choriomeningitis | 183 |
renal transplant | 183 |
confirmed cases | 182 |
viral entry | 182 |
patient care | 182 |
chronic hepatitis | 182 |
also found | 182 |
viral particles | 181 |
amino acids | 181 |
natural infection | 181 |
severe infections | 180 |
one patient | 179 |
fungal infection | 179 |
study group | 179 |
control study | 179 |
marrow transplant | 178 |
early diagnosis | 178 |
tissue culture | 178 |
airway inflammation | 177 |
laboratory mice | 177 |
adenovirus infection | 177 |
human influenza | 177 |
middle ear | 177 |
also known | 177 |
skin lesions | 176 |
heart disease | 176 |
commercially available | 176 |
hiv aids | 176 |
ng ml | 176 |
control practices | 176 |
viral clearance | 176 |
disease caused | 176 |
cov infection | 175 |
another study | 175 |
adaptive immunity | 174 |
personal protective | 174 |
may include | 174 |
pcr assay | 173 |
inflammatory responses | 173 |
severe combined | 172 |
neonatal sepsis | 172 |
also occur | 172 |
antiviral agents | 171 |
binding protein | 171 |
hcv infection | 171 |
infectious virus | 171 |
pulmonary infection | 171 |
family members | 171 |
protective immunity | 171 |
reverse transcription | 170 |
infection risk | 170 |
critical care | 170 |
patients receiving | 170 |
cerebrospinal fluid | 168 |
antiviral drugs | 168 |
virus vaccine | 168 |
white blood | 168 |
bowel disease | 167 |
mycoplasma pneumoniae | 167 |
blood culture | 167 |
antiretroviral therapy | 167 |
close contact | 167 |
acquired infections | 167 |
infection occurs | 167 |
infl ammation | 166 |
cell function | 166 |
widely used | 166 |
become infected | 165 |
organ failure | 165 |
diagnostic tests | 165 |
virus particles | 165 |
broad spectrum | 165 |
pcr assays | 165 |
respiratory diseases | 164 |
virus disease | 164 |
rabies virus | 164 |
study period | 164 |
drug resistance | 164 |
author funder | 163 |
blood cell | 163 |
median age | 163 |
rsv infections | 163 |
granted medrxiv | 163 |
significant differences | 163 |
cancer patients | 162 |
severe hepatitis | 162 |
signaling pathways | 162 |
cell proliferation | 162 |
factors associated | 162 |
reverse transcriptase | 162 |
per day | 162 |
virus isolation | 162 |
rna virus | 162 |
significant difference | 161 |
controlled trials | 161 |
mhc class | 161 |
high prevalence | 161 |
mouse hepatitis | 161 |
fatality rate | 160 |
advisory committee | 160 |
mean age | 160 |
intravenous immunoglobulin | 160 |
tissue damage | 160 |
laboratory animal | 160 |
viral genome | 159 |
coronavirus infections | 159 |
choriomeningitis virus | 159 |
copyright holder | 159 |
infections due | 158 |
previous studies | 158 |
clinical outcomes | 158 |
pleural effusion | 158 |
cell receptor | 158 |
cytomegalovirus infection | 158 |
retrospective study | 158 |
neutropenic patients | 157 |
pneumoniae infection | 157 |
mouse models | 157 |
reactive protein | 156 |
healthcare settings | 156 |
rhesus macaques | 156 |
young adults | 156 |
cell cultures | 156 |
chest radiograph | 155 |
rheumatoid arthritis | 155 |
killer cells | 155 |
definitive diagnosis | 155 |
adverse effects | 155 |
clinical samples | 155 |
venous catheters | 155 |
first year | 155 |
immune globulin | 155 |
parainfluenza viruses | 154 |
disease may | 154 |
bloodstream infection | 154 |
host factors | 154 |
viral diseases | 154 |
supportive care | 153 |
term care | 153 |
preterm infants | 153 |
leading cause | 153 |
adenovirus type | 152 |
cause severe | 152 |
like receptors | 152 |
protein kinase | 152 |
inflammatory bowel | 152 |
klebsiella pneumoniae | 152 |
may provide | 152 |
see chapter | 151 |
tritrichomonas foetus | 151 |
case reports | 150 |
mediated immunity | 150 |
infection among | 150 |
national institute | 150 |
specific antibodies | 150 |
standard precautions | 149 |
replacement therapy | 149 |
virus may | 148 |
infectious complications | 148 |
older adults | 148 |
children aged | 148 |
early stages | 148 |
face masks | 148 |
endemic areas | 147 |
lung tissue | 147 |
research complications | 147 |
class ii | 147 |
study showed | 147 |
randomized trial | 146 |
control group | 146 |
inflammatory cells | 146 |
liver failure | 146 |
japanese encephalitis | 145 |
made available | 145 |
blood samples | 145 |
emergency department | 145 |
intestinal tract | 145 |
human herpesvirus | 144 |
different types | 144 |
spinal cord | 144 |
naturally infected | 144 |
feline leukemia | 144 |
large numbers | 144 |
airborne transmission | 144 |
may play | 143 |
logistic regression | 143 |
version posted | 142 |
differentially expressed | 142 |
airway obstruction | 142 |
cell activation | 142 |
early stage | 142 |
blood vessels | 142 |
high fever | 142 |
specific antibody | 141 |
significantly lower | 141 |
may help | 141 |
rna polymerase | 141 |
acute care | 141 |
low birth | 141 |
also cause | 140 |
cellular immune | 140 |
two patients | 140 |
natural history | 140 |
two different | 140 |
fi rst | 139 |
two groups | 139 |
chronic lung | 139 |
social distancing | 138 |
shock syndrome | 138 |
hand washing | 138 |
older children | 138 |
pulmonary infections | 138 |
related infections | 138 |
time points | 138 |
often associated | 137 |
cell response | 137 |
acute otitis | 137 |
invasive aspergillosis | 137 |
red blood | 137 |
severe pneumonia | 137 |
acute lower | 137 |
university hospital | 136 |
viral dna | 136 |
proinflammatory cytokines | 136 |
determine whether | 136 |
low levels | 136 |
stem cells | 136 |
studies suggest | 136 |
hrv infection | 135 |
case fatality | 135 |
affected animals | 135 |
transplant recipient | 135 |
sequence analysis | 135 |
cell counts | 135 |
liver transplantation | 135 |
bovine viral | 135 |
dengue fever | 134 |
human cases | 134 |
drinking water | 134 |
within hours | 134 |
reported cases | 134 |
immune cell | 134 |
identifi ed | 134 |
virus strains | 133 |
year old | 133 |
negative bacilli | 133 |
following infection | 133 |
see table | 133 |
clinical specimens | 133 |
infections associated | 133 |
dengue infection | 133 |
immune dysregulation | 132 |
oxidative stress | 132 |
developed countries | 132 |
multiplex pcr | 132 |
abstract case | 132 |
person transmission | 132 |
human adenovirus | 132 |
south america | 132 |
well tolerated | 132 |
hendra virus | 132 |
laboratory animals | 132 |
report text | 132 |
results suggest | 132 |
herpes virus | 132 |
secondary infections | 131 |
human transmission | 131 |
year period | 131 |
nursing homes | 131 |
human beings | 131 |
growth factor | 131 |
resistant organisms | 131 |
exome sequencing | 131 |
may become | 130 |
pneumocystis carinii | 130 |
fi ndings | 130 |
nosocomial transmission | 130 |
randomised controlled | 130 |
infectious agent | 130 |
nasal discharge | 130 |
mast cells | 130 |
bronchial epithelial | 129 |
hbv infection | 129 |
combination therapy | 129 |
cause disease | 129 |
immunosorbent assay | 129 |
cryptosporidium parvum | 129 |
premature infants | 129 |
molecular epidemiology | 129 |
cell membrane | 128 |
surgical site | 128 |
may present | 128 |
may require | 128 |
viral disease | 127 |
adhesion molecule | 127 |
phase i | 127 |
environmental contamination | 126 |
metapneumovirus infection | 126 |
respiratory illnesses | 126 |
rsv bronchiolitis | 126 |
swine influenza | 126 |
healthy controls | 126 |
acquired immunodeficiency | 126 |
linked immunosorbent | 126 |
also observed | 126 |
domestic animals | 126 |
previously reported | 126 |
acute viral | 125 |
viral antigens | 125 |
patients treated | 125 |
rhinovirus colds | 125 |
immunodeficiency syndrome | 125 |
bronchiolitis obliterans | 125 |
viral antigen | 125 |
cord blood | 124 |
blood pressure | 124 |
diarrhea virus | 124 |
young infants | 124 |
syndrome virus | 124 |
lower airways | 124 |
emerging infectious | 123 |
wide variety | 123 |
bacterial meningitis | 123 |
pulmonary edema | 123 |
several days | 123 |
structural proteins | 123 |
adult mice | 123 |
canine distemper | 122 |
dendritic cell | 122 |
aged years | 122 |
severe sepsis | 122 |
viral protein | 122 |
important cause | 121 |
common variable | 121 |
resistant bacteria | 121 |
hsv infection | 121 |
oral route | 121 |
international license | 121 |
type iii | 121 |
body temperature | 121 |
twice daily | 120 |
immunocompromised hosts | 120 |
invasive fungal | 120 |
case series | 120 |
authors declare | 120 |
cell wall | 120 |
initial infection | 120 |
medical care | 120 |
disease burden | 120 |
first months | 120 |
evidence suggests | 119 |
target cells | 119 |
toxoplasma gondii | 119 |
nasal secretions | 119 |
varicella zoster | 119 |
susceptibility testing | 119 |
infection model | 119 |
human health | 119 |
clinical microbiology | 119 |
small animal | 119 |
laboratory findings | 119 |
three times | 119 |
cmv disease | 119 |
deficient mice | 118 |
tested positive | 118 |
viruses may | 118 |
host range | 118 |
human parainfluenza | 118 |
infectious mononucleosis | 118 |
room temperature | 118 |
patients without | 118 |
signaling pathway | 118 |
chest pain | 117 |
increased mortality | 117 |
human milk | 117 |
several weeks | 117 |
common respiratory | 117 |
significantly reduced | 117 |
critical role | 117 |
lg ml | 117 |
mast cell | 117 |
long term | 117 |
i ifns | 117 |
severe illness | 116 |
primary care | 116 |
herpes zoster | 116 |
necrotizing enterocolitis | 116 |
risk patients | 116 |
specific cd | 116 |
preventive measures | 116 |
killer cell | 116 |
myeloid cells | 116 |
virus vaccines | 116 |
contact precautions | 116 |
income countries | 115 |
environmental surfaces | 115 |
otherwise healthy | 115 |
blood mononuclear | 115 |
listeria monocytogenes | 115 |
endothelial cell | 115 |
toxic shock | 115 |
infection induces | 115 |
immunosuppressive therapy | 115 |
humoral immune | 115 |
kg day | 115 |
healthy adults | 114 |
respiratory system | 114 |
hepatic encephalopathy | 114 |
heart transplant | 114 |
granulomatous disease | 114 |
viral diarrhea | 114 |
viral culture | 114 |
taken together | 114 |
hospital infection | 113 |
serum antibody | 113 |
virus transmission | 113 |
clinical findings | 113 |
cells may | 113 |
foreign body | 113 |
immunodeficient mice | 113 |
nucleic acids | 113 |
virulence factors | 113 |
immune complexes | 113 |
situ hybridization | 112 |
currently available | 112 |
lymphoid tissue | 112 |
campylobacter jejuni | 112 |
antiviral treatment | 112 |
converting enzyme | 112 |
lassa fever | 112 |
equine encephalitis | 112 |
nonhuman primates | 112 |
potential role | 112 |
vitro activity | 112 |
fl uid | 111 |
induced asthma | 111 |
family history | 111 |
pathogenic avian | 111 |
haemorrhagic fever | 111 |
viral titers | 111 |
last years | 111 |
foreign bodies | 111 |
human infections | 111 |
biofilm formation | 111 |
human coronaviruses | 111 |
cellular immunity | 110 |
zikv infection | 110 |
serum samples | 110 |
positive results | 110 |
viral etiology | 110 |
healthy individuals | 110 |
many cases | 110 |
patients undergoing | 110 |
hospital stay | 110 |
inflammatory cytokine | 110 |
vero cells | 110 |
million people | 110 |
also may | 110 |
mouth disease | 110 |
high incidence | 110 |
primary immunodeficiencies | 110 |
less likely | 110 |
phylogenetic analysis | 110 |
adenovirus infections | 110 |
whole blood | 109 |
patients admitted | 109 |
real time | 109 |
cell lymphoma | 109 |
aids patients | 109 |
gross lesions | 109 |
environmental factors | 109 |
plasma cells | 109 |
also important | 109 |
high level | 109 |
ct scan | 109 |
nasal cavity | 109 |
antibiotic prophylaxis | 109 |
clinical data | 109 |
chronic bronchitis | 108 |
gene therapy | 108 |
treatment options | 108 |
molecular methods | 108 |
cells infected | 108 |
study conducted | 108 |
vaccine candidates | 108 |
chest radiographs | 108 |
binding lectin | 108 |
studies using | 108 |
small number | 108 |
children hospitalized | 108 |
severe infection | 108 |
expression levels | 108 |
receptor binding | 108 |
virus shedding | 108 |
care facility | 108 |
transmission occurs | 107 |
signifi cant | 107 |
rhodococcus equi | 107 |
pet birds | 107 |
acute lung | 107 |
contaminated food | 107 |
clinical outcome | 107 |
saudi arabia | 107 |
drug resistant | 107 |
reactive oxygen | 107 |
bacterial co | 107 |
signs include | 107 |
commonly associated | 107 |
fatal cases | 107 |
least two | 107 |
healthy children | 107 |
underlying disease | 107 |
infection due | 107 |
common clinical | 107 |
renal function | 106 |
may increase | 106 |
hospital admission | 106 |
secondary infection | 106 |
defense mechanisms | 106 |
patients received | 106 |
significant increase | 106 |
community acquired | 106 |
molecular biology | 106 |
first time | 106 |
transcription factor | 106 |
helicobacter pylori | 106 |
findings suggest | 106 |
virus entry | 106 |
significantly increased | 105 |
fatty acids | 105 |
acute exacerbations | 105 |
hsct recipients | 105 |
severe clinical | 105 |
dengue hemorrhagic | 105 |
lower airway | 105 |
rsv disease | 105 |
spectrum antibiotics | 105 |
immune status | 105 |
inclusion bodies | 105 |
mg ml | 105 |
liver function | 105 |
acinetobacter baumannii | 105 |
may reduce | 105 |
first infection | 105 |
highly contagious | 104 |
atopic dermatitis | 104 |
much higher | 104 |
risk assessment | 104 |
inflammatory mediators | 104 |
clinical illness | 104 |
european countries | 104 |
disseminated intravascular | 104 |
hematopoietic cell | 104 |
peer review | 104 |
new infections | 104 |
respiratory epithelium | 104 |
mouse colonies | 104 |
informed consent | 104 |
protein expression | 104 |
influenza vaccines | 104 |
old male | 104 |
analysis showed | 104 |
lamina propria | 104 |
disease transmission | 104 |
every hours | 104 |
recurrent wheezing | 103 |
test results | 103 |
antigen detection | 103 |
blood transfusion | 103 |
oral cavity | 103 |
chronic granulomatous | 103 |
candida species | 103 |
variable immunodeficiency | 103 |
porcine reproductive | 103 |
immunocompetent mice | 103 |
autoimmune diseases | 102 |
ex vivo | 102 |
pathological changes | 102 |
cotton rats | 102 |
early life | 102 |
experimental infections | 102 |
hydrogen peroxide | 102 |
age years | 102 |
active infection | 102 |
acute gastroenteritis | 102 |
candida albicans | 102 |
patient safety | 102 |
etiologic agent | 102 |
clinical diagnosis | 102 |
per cent | 102 |
viral hepatitis | 101 |
emerging infections | 101 |
diseases society | 101 |
south africa | 101 |
nasal mucosa | 101 |
surgical mask | 101 |
molecular mechanisms | 101 |
high rate | 101 |
lung infection | 101 |
molecular characterization | 101 |
many years | 101 |
viral persistence | 100 |
lyme disease | 100 |
protective effect | 100 |
observational study | 100 |
immune suppression | 100 |
many countries | 100 |
multiple organ | 100 |
children younger | 100 |
clinical syndromes | 100 |
salivary glands | 100 |
cryptosporidium infection | 100 |
plasma membrane | 100 |
less frequently | 100 |
single dose | 99 |
blood flow | 99 |
hmpv infection | 99 |
several months | 99 |
virus strain | 99 |
sickle cell | 99 |
first days | 99 |
less severe | 99 |
neuraminidase inhibitors | 99 |
virus titers | 99 |
better understanding | 99 |
effective treatment | 99 |
one case | 99 |
pg ml | 99 |
chemokine receptor | 99 |
cell subsets | 99 |
elderly patients | 98 |
lung cancer | 98 |
humoral immunity | 98 |
serious bacterial | 98 |
lavage fluid | 98 |
well known | 98 |
first described | 98 |
mouse strains | 98 |
relatively low | 98 |
many patients | 98 |
north american | 98 |
will also | 98 |
common causes | 98 |
surveillance system | 98 |
nursing home | 98 |
gestational age | 97 |
intravascular coagulation | 97 |
diagnostic testing | 97 |
febrile illness | 97 |
oral administration | 97 |
cytopathic effect | 97 |
day care | 97 |
animal species | 97 |
infect humans | 97 |
clinical significance | 97 |
respiratory protection | 97 |
maternal antibodies | 96 |
data collection | 96 |
human airway | 96 |
strains isolated | 96 |
liver transplant | 96 |
persistently infected | 96 |
healthcare personnel | 96 |
pneumococcal pneumonia | 96 |
immunoglobulin replacement | 96 |
passive immunity | 96 |
severe influenza | 96 |
lesions may | 96 |
severe rsv | 96 |
significant morbidity | 95 |
genetic diversity | 95 |
laboratory tests | 95 |
high frequency | 95 |
months old | 95 |
cryptococcus neoformans | 95 |
pulmonary tuberculosis | 95 |
human rhinoviruses | 95 |
also used | 95 |
old female | 95 |
immunosuppressed patients | 95 |
different species | 95 |
dna viruses | 95 |
one year | 95 |
weight infants | 95 |
epidemiological studies | 95 |
sars patients | 95 |
well established | 95 |
airway hyperresponsiveness | 95 |
two cases | 95 |
previously healthy | 95 |
cvid patients | 95 |
also reported | 94 |
successful treatment | 94 |
gold standard | 94 |
virus detection | 94 |
latent infection | 94 |
acute renal | 94 |
gel electrophoresis | 94 |
may show | 94 |
chronic disease | 94 |
autosomal recessive | 94 |
symptom onset | 94 |
positive patients | 94 |
recognition receptors | 94 |
renal disease | 94 |
asymptomatic infection | 94 |
remains unclear | 94 |
spike protein | 94 |
gastrointestinal symptoms | 94 |
antibody production | 94 |
takes place | 93 |
pathogenic bacteria | 93 |
also associated | 93 |
passive transfer | 93 |
infection results | 93 |
parenteral nutrition | 93 |
diagnostic methods | 93 |
higher levels | 93 |
red cell | 93 |
randomized clinical | 93 |
antimicrobial susceptibility | 93 |
serological tests | 93 |
invasive disease | 93 |
fusion protein | 93 |
intestinal mucosa | 93 |
convalescent plasma | 93 |
computed tomography | 93 |
infection caused | 93 |
viral agents | 93 |
uenza virus | 92 |
systemic infection | 92 |
typhoid fever | 92 |
positive samples | 92 |
infected persons | 92 |
prevent transmission | 92 |
time series | 92 |
cardiovascular disease | 92 |
medrxiv preprint | 92 |
gram negative | 92 |
borne encephalitis | 92 |
pattern recognition | 92 |
three patients | 92 |
animals may | 92 |
weight gain | 92 |
venous catheter | 92 |
lymphoid tissues | 92 |
oxygen species | 92 |
empiric therapy | 92 |
diarrheal disease | 92 |
ebv infection | 91 |
serious infections | 91 |
infectious bronchitis | 91 |
skin infections | 91 |
statistical analysis | 91 |
choroid plexus | 91 |
virus challenge | 91 |
upper airway | 91 |
newborn infants | 91 |
therapy may | 91 |
research council | 91 |
th responses | 91 |
streptococcus pyogenes | 91 |
antibody deficiency | 91 |
genetic testing | 91 |
antiviral drug | 91 |
antifungal therapy | 91 |
vitro studies | 91 |
alpha beta | 91 |
rapid diagnosis | 91 |
igg levels | 90 |
human lung | 90 |
giant cells | 90 |
higher incidence | 90 |
cell numbers | 90 |
allogeneic hematopoietic | 90 |
cell entry | 90 |
common colds | 90 |
rna genome | 90 |
sexually transmitted | 90 |
congenital heart | 90 |
immunodefi ciency | 90 |
high viral | 90 |
wild type | 90 |
low risk | 90 |
infection causes | 90 |
results showed | 89 |
recurrent respiratory | 89 |
patients hospitalized | 89 |
smooth muscle | 89 |
will help | 89 |
studies showed | 89 |
may need | 89 |
phase iii | 89 |
transcription factors | 89 |
days later | 89 |
years ago | 89 |
bordetella pertussis | 89 |
passive immunization | 89 |
mdck cells | 88 |
two major | 88 |
sudden death | 88 |
disseminated disease | 88 |
disease associated | 88 |
medical center | 88 |
acute hepatitis | 88 |
important factor | 88 |
respiratory epithelial | 88 |
diagnostic criteria | 88 |
congo hemorrhagic | 88 |
clinical management | 88 |
cynomolgus macaques | 87 |
samples collected | 87 |
protein synthesis | 87 |
endoplasmic reticulum | 87 |
multicenter study | 87 |
immune reconstitution | 87 |
antimicrobial activity | 87 |
pulmonary aspergillosis | 87 |
human cytomegalovirus | 87 |
antiviral effect | 87 |
rna replication | 87 |
phase ii | 87 |
clinical picture | 87 |
pediatric intensive | 87 |
children less | 87 |
two years | 87 |
negative staphylococci | 87 |
airway epithelium | 87 |
hepatocellular carcinoma | 86 |
whole exome | 86 |
scid mice | 86 |
mesenteric lymph | 86 |
vesicular stomatitis | 86 |
human papillomavirus | 86 |
healthcare facilities | 86 |
tissue infections | 86 |
experimental studies | 86 |
infant mice | 86 |
brain barrier | 85 |
key role | 85 |
cell type | 85 |
clinically relevant | 85 |
biomedical research | 85 |
primary immune | 85 |
viruses isolated | 85 |
significant risk | 85 |
transmission dynamics | 85 |
detection rate | 85 |
chronic liver | 85 |
significant reduction | 85 |
influenza season | 85 |
highly susceptible | 85 |
infants born | 85 |
national institutes | 85 |
positive bacteria | 85 |
increased levels | 85 |
membrane fusion | 85 |
umbilical cord | 85 |
presenting cells | 85 |
urinary catheters | 84 |
gastrointestinal disease | 84 |
prevent infection | 84 |
similar results | 84 |
based hand | 84 |
practice guidelines | 84 |
type infection | 84 |
cases per | 84 |
major histocompatibility | 84 |
aspergillus fumigatus | 84 |
infections occur | 84 |
findings include | 84 |
mcg ml | 84 |
antigen presentation | 84 |
human macrophages | 84 |
control strategies | 84 |
mediated immune | 83 |
capsid protein | 83 |
site infections | 83 |
southeast asia | 83 |
patients presenting | 83 |
atypical pneumonia | 83 |
genital tract | 83 |
th cells | 83 |
mycobacterium avium | 83 |
febrile infants | 83 |
influenza infections | 83 |
intercellular adhesion | 83 |
crucial role | 83 |
generation sequencing | 83 |
prospective cohort | 83 |
two weeks | 83 |
human cells | 83 |
murine model | 83 |
difficile infection | 83 |
felv infection | 83 |
denv infection | 83 |
suckling mice | 82 |
associated infection | 82 |
lesser extent | 82 |
disease pathogenesis | 82 |
alveolar epithelial | 82 |
chest ct | 82 |
may affect | 82 |
severely affected | 82 |
clostridium perfringens | 82 |
usually occurs | 82 |
clinical response | 82 |
infection associated | 82 |
medical records | 82 |
highly effective | 82 |
necropsy findings | 82 |
potential risk | 82 |
significantly different | 82 |
saharan africa | 82 |
carrier state | 82 |
transgenic mice | 82 |
frequently used | 82 |
stool samples | 81 |
lymphoid cells | 81 |
experimentally induced | 81 |
cryptosporidium spp | 81 |
commonly found | 81 |
host responses | 81 |
acute bronchiolitis | 81 |
virus rna | 81 |
many different | 81 |
signal transduction | 81 |
high morbidity | 81 |
cell lymphopenia | 81 |
vaccine candidate | 81 |
cells mm | 81 |
immune activation | 81 |
viral co | 81 |
chronic inflammation | 81 |
clinical use | 81 |
respiratory droplets | 81 |
reproduction number | 81 |
natural infections | 81 |
may represent | 81 |
pcr testing | 81 |
time rt | 81 |
animal health | 81 |
data indicate | 80 |
time point | 80 |
pulmonary function | 80 |
human immune | 80 |
bei der | 80 |
healthy volunteers | 80 |
differential diagnoses | 80 |
literature review | 80 |
animal studies | 80 |
respiratory samples | 80 |
nasopharyngeal aspirates | 80 |
teaching hospital | 80 |
cell differentiation | 80 |
transmitted via | 80 |
streptococcal infections | 80 |
mg day | 80 |
viral gastroenteritis | 80 |
protease inhibitors | 80 |
high dose | 80 |
early phase | 80 |
may explain | 80 |
confidence interval | 80 |
lactate dehydrogenase | 80 |
sars outbreak | 80 |
patient population | 80 |
resistant enterococci | 79 |
immune complex | 79 |
antimicrobial prophylaxis | 79 |
molecular techniques | 79 |
replication cycle | 79 |
liver enzymes | 79 |
primary human | 79 |
interferon alpha | 79 |
frequently associated | 79 |
connective tissue | 79 |
neurological disease | 79 |
sample size | 79 |
distemper virus | 79 |
asthmatic subjects | 79 |
also present | 79 |
post infection | 79 |
include fever | 79 |
like particles | 79 |
many studies | 79 |
tuberculosis infection | 79 |
national research | 79 |
particularly important | 79 |
antiviral effects | 79 |
also contribute | 79 |
highly active | 79 |
poorly understood | 78 |
may persist | 78 |
requiring hospitalization | 78 |
vaccine strain | 78 |
surgical masks | 78 |
infected individual | 78 |
nuclear factor | 78 |
cell tumors | 78 |
rotavirus infections | 78 |
i signaling | 78 |
drug administration | 78 |
allergic rhinitis | 78 |
medical history | 78 |
envelope protein | 78 |
disseminated infection | 78 |
hospital admissions | 78 |
mixed infections | 78 |
mice may | 78 |
enteric viruses | 78 |
isolation precautions | 78 |
immunization practices | 78 |
increased expression | 77 |
well documented | 77 |
organ dysfunction | 77 |
wild birds | 77 |
laboratory diagnosis | 77 |
first case | 77 |
hrv infections | 77 |
oxide synthase | 77 |
related bloodstream | 77 |
prospective studies | 77 |
study found | 77 |
allogeneic stem | 77 |
cell activity | 77 |
chronic infections | 77 |
long periods | 77 |
host immunity | 77 |
asthma exacerbation | 77 |
aedes aegypti | 77 |
human monoclonal | 77 |
nasal swabs | 77 |
two main | 77 |
enveloped viruses | 77 |
immune evasion | 77 |
fatality rates | 77 |
antiviral response | 77 |
intestinal epithelial | 77 |
vascular permeability | 77 |
airway disease | 77 |
elderly people | 77 |
hbov infection | 77 |
relative risk | 77 |
viral pathogenesis | 77 |
watery diarrhea | 77 |
hygiene practices | 77 |
icu patients | 77 |
chronic diarrhea | 77 |
increased incidence | 76 |
survival rate | 76 |
higher rates | 76 |
much less | 76 |
antiviral immunity | 76 |
lymphocyte subsets | 76 |
detection methods | 76 |
activated protein | 76 |
plasmacytoid dendritic | 76 |
commonly seen | 76 |
lung inflammation | 76 |
study reported | 76 |
single infection | 76 |
broad range | 76 |
many viruses | 76 |
chronic diseases | 76 |
live virus | 76 |
readily available | 76 |
bordetella bronchiseptica | 76 |
effi cacy | 76 |
negative results | 76 |
additional file | 76 |
serum igg | 76 |
canine herpesvirus | 76 |
infected cell | 76 |
new cases | 76 |
clinical improvement | 76 |
blood count | 76 |
cause significant | 76 |
transmission rate | 76 |
chlamydia trachomatis | 76 |
past years | 75 |
one third | 75 |
disease course | 75 |
newcastle disease | 75 |
antiviral responses | 75 |
virus bronchiolitis | 75 |
cell infiltration | 75 |
causative organism | 75 |
stimulating factor | 75 |
acquired infection | 75 |
resistance among | 75 |
health problem | 75 |
i interferons | 75 |
highly infectious | 75 |
throat swabs | 75 |
negative pressure | 75 |
venezuelan equine | 75 |
genome sequence | 75 |
clinical presentations | 75 |
higher mortality | 75 |
tract symptoms | 75 |
global burden | 75 |
comparative study | 74 |
may appear | 74 |
antimicrobial treatment | 74 |
enzyme immunoassay | 74 |
cells ul | 74 |
hemolytic anemia | 74 |
lymphocyte counts | 74 |
neonatal mice | 74 |
chronically infected | 74 |
viral hemorrhagic | 74 |
knockout mice | 74 |
identifi cation | 74 |
rubella virus | 74 |
patients showed | 74 |
respiratory pathogen | 74 |
airborne infection | 74 |
cd counts | 74 |
rhesus monkeys | 74 |
therapeutic agents | 74 |
severely ill | 74 |
generation cephalosporins | 74 |
host species | 74 |
south korea | 74 |
competing interests | 74 |
pathologic findings | 74 |
salmonella typhimurium | 74 |
cytokine responses | 74 |
study design | 74 |
determined using | 74 |
infection include | 73 |
sialic acid | 73 |
th century | 73 |
within weeks | 73 |
histocompatibility complex | 73 |
risk groups | 73 |
insertion site | 73 |
major role | 73 |
candida spp | 73 |
vast majority | 73 |
hiv transmission | 73 |
immunocompromised host | 73 |
animal medicine | 73 |
igm antibodies | 73 |
contaminated water | 73 |
protective role | 73 |
odds ratio | 73 |
per patient | 73 |
therapeutic strategies | 73 |
better understand | 73 |
lupus erythematosus | 73 |
renal transplantation | 73 |
also showed | 73 |
opportunistic pathogens | 73 |
rapid detection | 73 |
aerosolized ribavirin | 73 |
applied biosystems | 73 |
hcv rna | 73 |
bl mice | 73 |
drug interactions | 73 |
specific treatment | 73 |
transmission via | 73 |
ns protein | 73 |
stranded dna | 73 |
healthcare professionals | 72 |
older patients | 72 |
spectrum beta | 72 |
specific pathogen | 72 |
fatal disease | 72 |
predictive value | 72 |
elevated levels | 72 |
alveolar damage | 72 |
significantly associated | 72 |
ebov infection | 72 |
antibody titer | 72 |
usually associated | 72 |
infections including | 72 |
one virus | 72 |
working group | 72 |
cell development | 72 |
pneumonia caused | 72 |
highly conserved | 72 |
nosocomial pneumonia | 72 |
may contain | 72 |
igg antibodies | 72 |
cell populations | 72 |
studies show | 72 |
recent report | 72 |
like virus | 72 |
less commonly | 71 |
early childhood | 71 |
serum levels | 71 |
immunodeficiency diseases | 71 |
described previously | 71 |
index case | 71 |
national health | 71 |
binding site | 71 |
controlled study | 71 |
older persons | 71 |
human population | 71 |
dependent manner | 71 |
care providers | 71 |
contact tracing | 71 |
bronchitis virus | 71 |
hospital environment | 71 |
infected person | 71 |
often present | 71 |
future studies | 71 |
hematologic malignancies | 71 |
first years | 71 |
antibiotic susceptibility | 70 |
naturally acquired | 70 |
will develop | 70 |
hours post | 70 |
may induce | 70 |
zoonotic potential | 70 |
multivariate analysis | 70 |
complement fixation | 70 |
antibody levels | 70 |
also occurs | 70 |
feline infectious | 70 |
greater risk | 70 |
rna synthesis | 70 |
several years | 70 |
inflammatory process | 70 |
infected host | 70 |
several factors | 70 |
specific immune | 70 |
four patients | 70 |
diffi cult | 70 |
inflammatory disease | 70 |
statistical significance | 70 |
nasal congestion | 70 |
data analysis | 70 |
containment measures | 70 |
new zealand | 70 |
fold increase | 70 |
long time | 70 |
next generation | 70 |
positive blood | 70 |
attenuated live | 70 |
like symptoms | 70 |
lethal infection | 69 |
third trimester | 69 |
study demonstrated | 69 |
gut microbiota | 69 |
high doses | 69 |
first month | 69 |
first trimester | 69 |
positive cases | 69 |
virus ns | 69 |
first week | 69 |
autosomal dominant | 69 |
antibiotic prescribing | 69 |
pleural effusions | 69 |
lung parenchyma | 69 |
diagnostic test | 69 |
cell immunity | 69 |
adhesion molecules | 69 |
control programs | 69 |
infected birds | 69 |
medical conditions | 69 |
infectious peritonitis | 69 |
wound healing | 69 |
practices advisory | 69 |
host disease | 69 |
southern china | 69 |
asymptomatic infections | 69 |
digestive tract | 69 |
hospital setting | 69 |
higher rate | 69 |
clinical study | 69 |
pulmonary syndrome | 69 |
growth rate | 69 |
complete blood | 69 |
recent advances | 69 |
highly sensitive | 69 |
common pathogens | 68 |
clinical impact | 68 |
human populations | 68 |
west africa | 68 |
pulmonary lesions | 68 |
blood products | 68 |
zoonotic disease | 68 |
cytokine release | 68 |
prophylactic antibiotics | 68 |
ifn production | 68 |
infect dis | 68 |
remains unknown | 68 |
resistant gram | 68 |
clinically significant | 68 |
analyzed using | 68 |
perfringens type | 68 |
systematic reviews | 68 |
herd immunity | 68 |
immunocompromised individuals | 68 |
also seen | 68 |
microscopic examination | 68 |
enteric pathogens | 68 |
carinii pneumonia | 68 |
disease occurs | 68 |
interferon response | 68 |
acute diarrhea | 68 |
nucleotide sequence | 68 |
million cases | 68 |
regulatory factor | 68 |
sectional study | 68 |
overall mortality | 68 |
like viruses | 68 |
chronic respiratory | 68 |
necrotizing fasciitis | 68 |
clinical syndrome | 68 |
studies conducted | 68 |
frequently detected | 68 |
bacterial colonization | 68 |
platelet count | 68 |
environmental conditions | 68 |
culture results | 68 |
normal range | 68 |
reverse genetics | 68 |
disease due | 68 |
cfu ml | 68 |
breast cancer | 68 |
new coronavirus | 68 |
hantavirus pulmonary | 68 |
chronic inflammatory | 68 |
infection also | 68 |
mortality among | 68 |
chv infection | 68 |
lung epithelial | 68 |
high rates | 67 |
different cell | 67 |
specific igg | 67 |
low level | 67 |
signs may | 67 |
least days | 67 |
pulmonary hypertension | 67 |
severe dengue | 67 |
may involve | 67 |
respiratory signs | 67 |
days postinfection | 67 |
less frequent | 67 |
data regarding | 67 |
protease inhibitor | 67 |
two distinct | 67 |
early onset | 67 |
therapeutic options | 67 |
immune systems | 67 |
also possible | 67 |
observational studies | 67 |
fluorescent antibody | 67 |
first wave | 67 |
cotton rat | 67 |
enteric infections | 67 |
first report | 67 |
diffuse alveolar | 67 |
causative agents | 67 |
attack rate | 67 |
maternal antibody | 67 |
genetic analysis | 67 |
large amounts | 67 |
brain tissue | 67 |
face mask | 67 |
also shown | 67 |
bovine respiratory | 67 |
pasteurella multocida | 67 |
hygiene compliance | 67 |
often used | 67 |
relatively high | 67 |
acute asthma | 67 |
invasive procedures | 66 |
eye protection | 66 |
available data | 66 |
gram stain | 66 |
among infants | 66 |
single infections | 66 |
experimental inoculation | 66 |
infected tissues | 66 |
aspiration pneumonia | 66 |
systemic disease | 66 |
like syndrome | 66 |
rotavirus vaccine | 66 |
psittacine birds | 66 |
expressed breast | 66 |
different strains | 66 |
virus isolated | 66 |
early detection | 66 |
small molecule | 66 |
fatty acid | 66 |
kidney disease | 66 |
retrospective analysis | 66 |
health authorities | 66 |
mortality associated | 66 |
elderly persons | 66 |
may vary | 66 |
study using | 66 |
veterinary medicine | 66 |
lassa virus | 66 |
much lower | 66 |
virus production | 66 |
tertiary care | 66 |
relative humidity | 65 |
st century | 65 |
widespread use | 65 |
recombinant human | 65 |
adenoviral infection | 65 |
years later | 65 |
studies indicate | 65 |
memory cd | 65 |
fruit bats | 65 |
unclear whether | 65 |
month period | 65 |
aerosol transmission | 65 |
infectious dose | 65 |
monkeypox virus | 65 |
type diabetes | 65 |
cell disease | 65 |
acquired respiratory | 65 |
will need | 65 |
acute illness | 65 |
inflammatory cell | 65 |
neuraminidase inhibitor | 65 |
defi ned | 65 |
novel human | 65 |
retrospective cohort | 65 |
infi ltration | 65 |
parasitic infections | 65 |
congestive heart | 65 |
aspergillus spp | 65 |
clinical evidence | 65 |
zoonotic transmission | 65 |
expression profiles | 65 |
wide spectrum | 65 |
day post | 65 |
may reveal | 65 |
hearing loss | 65 |
unknown origin | 65 |
global health | 65 |
aids related | 65 |
different countries | 65 |
virus causes | 65 |
small intestinal | 65 |
tract illness | 65 |
neurological signs | 65 |
mammalian cells | 65 |
phagocytic cells | 65 |
may serve | 64 |
conjugate vaccine | 64 |
important risk | 64 |
binding domain | 64 |
resistant enterococcus | 64 |
wound infections | 64 |
pneumococcal vaccine | 64 |
exact test | 64 |
affecting humans | 64 |
among others | 64 |
clinical relevance | 64 |
winter months | 64 |
cleavage site | 64 |
independent risk | 64 |
well understood | 64 |
interferon gamma | 64 |
times higher | 64 |
complement activation | 64 |
lung infections | 64 |
hela cells | 64 |
nasopharyngeal swabs | 64 |
common bacterial | 64 |
lymphocyte count | 64 |
clinical severity | 64 |
microbiology laboratory | 64 |
susceptible individuals | 64 |
indirect contact | 64 |
acute disease | 64 |
lung pathology | 64 |
neisseria meningitidis | 64 |
dairy cattle | 64 |
infection compared | 64 |
surface antigen | 64 |
severe lower | 64 |
lower levels | 64 |
borrelia burgdorferi | 64 |
short term | 64 |
log reduction | 64 |
bal fluid | 64 |
incidence rate | 63 |
susceptible population | 63 |
highest risk | 63 |
viruses cause | 63 |
antimicrobial stewardship | 63 |
passive immunotherapy | 63 |
household contacts | 63 |
salmonella spp | 63 |
greatest risk | 63 |
streptococcal pharyngitis | 63 |
first line | 63 |
also play | 63 |
respiratory specimens | 63 |
operating room | 63 |
heart rate | 63 |
liver injury | 63 |
specific antiviral | 63 |
kidney transplant | 63 |
serratia marcescens | 63 |
lung tissues | 63 |
treated mice | 63 |
last decade | 63 |
limited data | 63 |
type virus | 63 |
tissue samples | 63 |
serologic testing | 63 |
different viruses | 63 |
allergic inflammation | 63 |
antimicrobial peptides | 63 |
first isolated | 63 |
host defenses | 62 |
ocular surface | 62 |
probiotic strains | 62 |
coronavirus oc | 62 |
systemic lupus | 62 |
patients develop | 62 |
diagnostic tool | 62 |
gene products | 62 |
among hospitalized | 62 |
fecal samples | 62 |
immunocompromised children | 62 |
cause respiratory | 62 |
acute bacterial | 62 |
bacterial growth | 62 |
associated urinary | 62 |
resistant isolates | 62 |
host population | 62 |
times daily | 62 |
vaccination programs | 62 |
plasmodium falciparum | 62 |
possible role | 62 |
differential expression | 62 |
lumbar puncture | 62 |
infective endocarditis | 62 |
well described | 62 |
active surveillance | 62 |
vaccine efficacy | 62 |
three different | 62 |
viral detection | 62 |
lung biopsy | 61 |
treated patients | 61 |
bactericidal activity | 61 |
molecular patterns | 61 |
patient populations | 61 |
copies ml | 61 |
routine use | 61 |
salivary gland | 61 |
controlled studies | 61 |
based study | 61 |
acinetobacter spp | 61 |
affected patients | 61 |
stomatitis virus | 61 |
low cd | 61 |
also detected | 61 |
current study | 61 |
will provide | 61 |
pilot study | 61 |
normal flora | 61 |
care centers | 61 |
inbred strains | 61 |
respiratory rate | 61 |
pid patients | 61 |
resistance genes | 61 |
onset sepsis | 61 |
blood donors | 61 |
medical staff | 61 |
systemic inflammatory | 61 |
virus encephalitis | 61 |
reservoir hosts | 61 |
infection will | 61 |
disease outbreaks | 61 |
parainfl uenza | 61 |
mononuclear cell | 61 |
domestic cats | 61 |
liver diseases | 61 |
first step | 61 |
norwalk virus | 61 |
tumour necrosis | 61 |
shiga toxin | 60 |
environmental cleaning | 60 |
cell cycle | 60 |
disease process | 60 |
cell adhesion | 60 |
children infected | 60 |
attenuated vaccines | 60 |
five years | 60 |
dependent enhancement | 60 |
myocardial infarction | 60 |
related infection | 60 |
mrna expression | 60 |
laboratory mouse | 60 |
two decades | 60 |
sense rna | 60 |
time period | 60 |
portal hypertension | 60 |
ige levels | 60 |
acquired immune | 60 |
year study | 60 |
corona virus | 60 |
antifungal agents | 60 |
among healthcare | 60 |
pneumocystis jiroveci | 60 |
acute infections | 60 |
first reported | 60 |
hpv infection | 60 |
control subjects | 60 |
may act | 60 |
hospitalized infants | 60 |
catheter insertion | 60 |
liver cirrhosis | 60 |
longitudinal study | 60 |
interferon signaling | 60 |
inhibitory effect | 60 |
associated molecular | 60 |
hospitalised patients | 60 |
spotted fever | 60 |
metabolic acidosis | 60 |
tmp smx | 60 |
cd cell | 59 |
virus outbreak | 59 |
experimental models | 59 |
marburg virus | 59 |
common viral | 59 |
copy number | 59 |
factor alpha | 59 |
antigenic drift | 59 |
matrix protein | 59 |
zoonotic diseases | 59 |
million deaths | 59 |
pneumococcal disease | 59 |
virus pneumonia | 59 |
persistent infections | 59 |
preventing transmission | 59 |
significantly reduce | 59 |
old boy | 59 |
potential therapeutic | 59 |
oxygen saturation | 59 |
human herpes | 59 |
may produce | 59 |
nested pcr | 59 |
infected cases | 59 |
fi brosis | 59 |
reduced susceptibility | 59 |
spectrum antiviral | 59 |
less effective | 59 |
several different | 59 |
pulmonary complications | 59 |
dental practice | 59 |
electron microscopic | 59 |
health service | 59 |
inactivated vaccine | 59 |
bacterial species | 59 |
lung diseases | 59 |
host interactions | 59 |
one must | 59 |
horizontal transmission | 59 |
care setting | 59 |
also lead | 59 |
infection transmission | 59 |
one health | 58 |
mrsa isolates | 58 |
fatal outcome | 58 |
cell carcinoma | 58 |
life threatening | 58 |
human rotavirus | 58 |
must also | 58 |
mycobacterial infection | 58 |
cd expression | 58 |
antibody therapy | 58 |
chronic pulmonary | 58 |
hiv disease | 58 |
viral envelope | 58 |
signifi cantly | 58 |
analysis revealed | 58 |
virus isolates | 58 |
neutrophil count | 58 |
genome sequencing | 58 |
infection via | 58 |
american academy | 58 |
asthmatic children | 58 |
postexposure prophylaxis | 58 |
tissue tropism | 58 |
appropriate antibiotic | 58 |
chest radiography | 58 |
results indicate | 58 |
neonatal infection | 58 |
hepatic lipidosis | 58 |
kupffer cells | 58 |
lcmv infection | 58 |
also demonstrated | 58 |
subsequent infection | 58 |
close contacts | 58 |
molecular weight | 58 |
faecal samples | 58 |
dry cough | 58 |
virus infected | 58 |
home care | 58 |
heparan sulfate | 58 |
chronic viral | 58 |
economic impact | 58 |
diagnostic techniques | 58 |
pneumonia may | 58 |
mediated endocytosis | 58 |
salmonella infection | 58 |
developing world | 58 |
older age | 58 |
natural host | 58 |
may take | 58 |
may predispose | 58 |
cells expressing | 57 |
poor prognosis | 57 |
cause acute | 57 |
amniotic fluid | 57 |
induced disease | 57 |
acute onset | 57 |
may influence | 57 |
cells via | 57 |
pcr products | 57 |
nutritional status | 57 |
liver biopsy | 57 |
ist die | 57 |
related complications | 57 |
factors may | 57 |
severe complications | 57 |
approximately one | 57 |
field gel | 57 |
six months | 57 |
laboratory testing | 57 |
old girl | 57 |
small cell | 57 |
biological materials | 57 |
study also | 57 |
grade fever | 57 |
surgical procedures | 57 |
gene segments | 57 |
symptoms include | 57 |
neonatal infections | 57 |
death rate | 57 |
current evidence | 57 |
simultaneous detection | 57 |
infectious causes | 57 |
endemic area | 57 |
blood gas | 57 |
severe pulmonary | 57 |
prevention climate | 57 |
symptoms may | 57 |
sudden onset | 57 |
might also | 57 |
commonly reported | 57 |
pandemic virus | 57 |
epidemiological data | 57 |
inflammatory diseases | 57 |
lesions include | 57 |
significant role | 57 |
weeks later | 57 |
acid amplification | 57 |
among adults | 57 |
lymphocyte proliferation | 57 |
norovirus infection | 56 |
using pcr | 56 |
infection without | 56 |
nude mice | 56 |
will require | 56 |
small bowel | 56 |
cell depletion | 56 |
major risk | 56 |
diffuse interstitial | 56 |
pneumonia virus | 56 |
gastrointestinal infections | 56 |
emerging viral | 56 |
skin test | 56 |
inactivated influenza | 56 |
physical activity | 56 |
effective infection | 56 |
emerging viruses | 56 |
neurological symptoms | 56 |
latent infections | 56 |
membrane protein | 56 |
associated coronavirus | 56 |
genetic material | 56 |
rrna gene | 56 |
newborn screening | 56 |
natural reservoir | 56 |
common infections | 56 |
pneumoniae infections | 56 |
intranasal inoculation | 56 |
human monocytes | 56 |
genes involved | 56 |
lower risk | 56 |
molecular basis | 56 |
without clinical | 56 |
elevated serum | 56 |
epidemiologic studies | 56 |
agents may | 56 |
two strains | 56 |
based precautions | 56 |
quaternary ammonium | 56 |
fiv infection | 56 |
may remain | 56 |
infection within | 56 |
give rise | 56 |
active antiretroviral | 56 |
cd ra | 56 |
likely due | 56 |
stimulated genes | 56 |
infection spread | 56 |
molecular analysis | 56 |
genes encoding | 56 |
bacterial contamination | 56 |
droplet precautions | 55 |
liver damage | 55 |
cells ml | 55 |
asthmatic patients | 55 |
american society | 55 |
aldrich syndrome | 55 |
etiologic agents | 55 |
diagnosis may | 55 |
cohort studies | 55 |
often seen | 55 |
surveillance data | 55 |
tissue injury | 55 |
small ruminants | 55 |
intranasal administration | 55 |
ifn signaling | 55 |
cases reported | 55 |
table i | 55 |
wnv infection | 55 |
protective efficacy | 55 |
clinical manifestation | 55 |
capsid proteins | 55 |
care hospitals | 55 |
significantly decreased | 55 |
sporadic cases | 55 |
infants younger | 55 |
host defence | 55 |
infected macrophages | 55 |
hand rub | 55 |
mainland china | 55 |
treatment failure | 55 |
mass spectrometry | 55 |
mrsa strains | 55 |
patients will | 55 |
congenital infection | 55 |
one week | 55 |
dependent rna | 55 |
dna vaccines | 55 |
one hundred | 55 |
aureus infections | 55 |
systemic inflammation | 55 |
new insights | 55 |
fluid therapy | 55 |
case study | 55 |
diseases caused | 55 |
encephalomyelitis virus | 55 |
improved survival | 55 |
positive cocci | 55 |
take place | 55 |
point mutations | 55 |
opportunistic infection | 55 |
cytokine levels | 55 |
three groups | 55 |
blood transfusions | 55 |
mechanisms underlying | 55 |
biopsy samples | 55 |
novel influenza | 55 |
laboratory studies | 55 |
neutrophil extracellular | 55 |
highly variable | 54 |
companion animals | 54 |
serologic evidence | 54 |
reservoir host | 54 |
protective immune | 54 |
highly virulent | 54 |
intermediate hosts | 54 |
dengue viruses | 54 |
sexual transmission | 54 |
mucous membrane | 54 |
hospital acquired | 54 |
surveillance study | 54 |
like disease | 54 |
studies revealed | 54 |
wild animals | 54 |
see section | 54 |
immune serum | 54 |
universal precautions | 54 |
invasive infections | 54 |
young age | 54 |
one may | 54 |
meningococcal disease | 54 |
common among | 54 |
sample collection | 54 |
clinical immunology | 54 |
nonhuman primate | 54 |
acute bronchitis | 54 |
immunoglobulin levels | 54 |
mild disease | 54 |
legionella pneumophila | 54 |
antiviral immune | 54 |
bat species | 54 |
mucus production | 54 |
animals will | 54 |
high concentrations | 54 |
streptococcal infection | 54 |
chart review | 54 |
cell leukemia | 54 |
target cell | 54 |
children years | 54 |
infected population | 54 |
lessons learned | 54 |
laboratory workers | 54 |
control practice | 54 |
vascular endothelial | 54 |
herpes viruses | 54 |
blood stream | 54 |
kidney cells | 54 |
icu admission | 54 |
abscess formation | 54 |
treatment strategies | 54 |
cd count | 53 |
two studies | 53 |
magnetic resonance | 53 |
igg antibody | 53 |
ethics committee | 53 |
aspergillus species | 53 |
virus load | 53 |
influenza surveillance | 53 |
patients aged | 53 |
cell receptors | 53 |
lipid metabolism | 53 |
adverse reactions | 53 |
cytokine response | 53 |
hemagglutination inhibition | 53 |
successfully treated | 53 |
mycobacterial infections | 53 |
viral pathogen | 53 |
intermediate host | 53 |
cold symptoms | 53 |
influenza pneumonia | 53 |
three cases | 53 |
personal hygiene | 53 |
limited number | 53 |
lymphoproliferative disease | 53 |
immune mechanisms | 53 |
york city | 53 |
infected infants | 53 |
underlying cause | 53 |
effective vaccine | 53 |
east asia | 53 |
host cellular | 53 |
virus pathogenesis | 53 |
newly discovered | 53 |
induced sputum | 53 |
expert opinion | 53 |
days prior | 53 |
empiric treatment | 53 |
clinical setting | 53 |
renal dysfunction | 53 |
preterm neonates | 53 |
serologic tests | 53 |
septic arthritis | 53 |
personal responsibility | 53 |
visceral leishmaniasis | 53 |
inactivated vaccines | 53 |
cardiac surgery | 53 |
common pathogen | 53 |
etiological agent | 53 |
macrophage activation | 53 |
red cells | 53 |
latin america | 53 |
severe symptoms | 53 |
death due | 53 |
viral gene | 53 |
hmpv infections | 53 |
autoimmune disease | 53 |
dual infection | 53 |
ct scans | 53 |
contaminated surfaces | 53 |
open reading | 53 |
treatment may | 53 |
inhibitory concentration | 53 |
prolonged periods | 53 |
care hospital | 53 |
hiv infected | 53 |
oral transmission | 52 |
chlamydia psittaci | 52 |
factors include | 52 |
clinical laboratory | 52 |
every year | 52 |
disease prevention | 52 |
hemorrhagic fevers | 52 |
human adenoviruses | 52 |
usually present | 52 |
high degree | 52 |
diagnostic tools | 52 |
genetic variability | 52 |
viral strains | 52 |
viral upper | 52 |
reproductive tract | 52 |
embryo transfer | 52 |
effective vaccines | 52 |
bronchopulmonary dysplasia | 52 |
interferon regulatory | 52 |
intestinal disease | 52 |
occurs within | 52 |
also affect | 52 |
new therapeutic | 52 |
climate change | 52 |
throat swab | 52 |
early treatment | 52 |
patients developed | 52 |
clinical aspects | 52 |
drug therapy | 52 |
macrolide resistance | 52 |
serological evidence | 52 |
predisposing factors | 52 |
candida infections | 52 |
mrsa infections | 52 |
african green | 52 |
th cytokine | 52 |
regression model | 52 |
child transmission | 52 |
mild symptoms | 52 |
endotracheal intubation | 52 |
droplet nuclei | 52 |
extremely low | 52 |
average number | 52 |
first weeks | 52 |
viral coinfection | 52 |
may indicate | 52 |
human parvovirus | 52 |
virus antigen | 52 |
recent data | 52 |
additional studies | 52 |
patient contact | 52 |
two species | 52 |
pcr tests | 52 |
ms patients | 52 |
serine protease | 52 |
increased viral | 52 |
hygiene promotion | 52 |
increasing number | 52 |
confi rmed | 52 |
rsv vaccine | 52 |
drug delivery | 51 |
specific viral | 51 |
prevention strategies | 51 |
rapid diagnostic | 51 |
will continue | 51 |
venous access | 51 |
may benefit | 51 |
three types | 51 |
children may | 51 |
new world | 51 |
mouse strain | 51 |
pdm virus | 51 |
invasive pulmonary | 51 |
infection group | 51 |
descriptive study | 51 |
associated disease | 51 |
diagnostic procedures | 51 |
previously published | 51 |
infection human | 51 |
minute virus | 51 |
human body | 51 |
pneumococcal conjugate | 51 |
goat kids | 51 |
igg subclass | 51 |
laboratory rodents | 51 |
dengue vaccine | 51 |
site infection | 51 |
infection cases | 51 |
wild mice | 51 |
current knowledge | 51 |
pediatric population | 51 |
basement membrane | 51 |
cardiac output | 51 |
early infection | 51 |
strand rna | 51 |
will likely | 51 |
infection remains | 51 |
fold higher | 51 |
related diseases | 51 |
forming units | 51 |
canine parvovirus | 51 |
associated diarrhea | 51 |